Search all CIRM Grants

Institution Researcher name Grant Type Grant Title Award Value
ViaCyte, Inc. Howard Foyt Strategic Partnership I Preclinical and clinical testing of a stem cell-based combination product for insulin-dependent diabetes $10,075,070
Sanford-Burnham Medical Research Institute Stuart Lipton Early Translational IV Programming Human ESC-derived Neural Stem Cells with MEF2C for Transplantation in Stroke $2,124,000
University of California, San Diego Thomas Kipps Disease Team Therapy Development III Therapeutic Eradication of Cancer Stem Cells $4,179,598
Stanford University Michele Calos Early Translational IV Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B $1,876,253
University of California, Los Angeles James Dunn Tools and Technologies III Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction $1,818,751
University of California, Davis Kyriacos Athanasiou Early Translational III Tissue engineered cartilage from autologous, dermis-isolated, adult, stem (DIAS) cells $1,735,703
University of California, San Diego Shyni Varghese New Faculty II A Novel Microenvironment-Mediated Functional Skeletal Muscle from Human Embryonic Stem Cells and their In Vivo Engraftment $2,300,569
Beckman Research Institute of City of Hope Stephen Forman Early Translational III Targeting glioma cancer stem cells with receptor-engineered self-renewing memory T cells $5,217,004
University of California, San Diego Shu Chien Tools and Technologies II Development of Synthetic Microenvironments for Stem Cell Growth and Differentiation $1,706,628
The Salk Institute for Biological Studies David Schubert Early Translational III Stem cell based small molecule therapy for Alzheimer's disease $1,673,757
Stanford University Judith Shizuru Disease Team Therapy Development - Research A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants $19,068,382
Cellular Dynamics International Thomas Novak hiPSC Derivation Generation and characterization of high-quality, footprint-free human induced pluripotent stem cell lines from 3,000 donors to investigate multigenic diseases $16,000,000
Numerate, Inc. John Griffin Early Translational IV Use of human iPSC-derived neurons from Huntington’s Disease patients to develop novel, disease-modifying small molecule structural corrector drug candidates targeting the unique, neurotoxic conformation of mutant huntingtin $938,391
Human BioMolecular Research Institute John Cashman Early Translational IV Improving Existing Drugs for Long QT Syndrome type 3 (LQT3) by hiPSC Disease-in-Dish Model $6,361,369
Stanford University Howard Chang Basic Biology IV Long noncoding RNAs for pluripotency and cell fate commitment $1,386,627
Coriell Institute for Medical Research Dorit Berlin hPSC Repository The CIRM Human Pluripotent Stem Cell Biorepository – A Resource for Safe Storage and Distribution of High Quality iPSCs $9,942,175
The J. David Gladstone Institutes Sheng Ding Basic Biology IV A new paradigm of lineage-specific reprogramming $1,708,560
University of California, Los Angeles Stanley Nelson Early Translational from Disease Team Conversion Combination therapy to Enhance Antisense Mediated Exon Skipping for Duchenne Muscular Dystrophy $1,823,545
Stanford University Ching-Pin Chang New Faculty II VEGF signaling in adventitial stem cells in vascular physiology and disease $3,005,695
Scripps Research Institute Kristin Baldwin Basic Biology III Identifying sources of mutation in human induced pluripotent stem cells by whole genome sequencing $1,705,500
University of California, San Diego Ananda Goldrath Basic Biology IV Mechanisms to protect hESC-derived cells from allogenic immune rejection $1,161,000
The J. David Gladstone Institutes Sheng Ding Basic Biology V A novel druggable mechanism to safeguard stem cell genome $1,423,800
Stanford University Aaron Hsueh Basic Biology III Correlated time-lapse imaging and single cell molecular analysis of human embryo development $1,259,764
Scripps Research Institute Peter Schultz Early Translational III Targeting Stem Cells to Enhance Remyelination in the Treatment of Multiple Sclerosis $2,623,242
University of Southern California Robert Maxson Training Grant I-1 CIRM Stem Cell Biology Training Grant $2,332,431
Stanford University Michele Calos Early Translational II Stem Cell Therapy for Duchenne Muscular Dystrophy $2,267,261
California Institute of Technology David Tirrell Basic Biology V Engineered matrices for control of lineage commitment in human pancreatic stem cells $526,896
The J. David Gladstone Institutes Benoit Bruneau Basic Biology IV Epigenetic regulation of human cardiac differentiation $1,708,560
The J. David Gladstone Institutes Steven Finkbeiner Early Translational IV Development of Novel Autophagy Inducers to Block the Progression of and Treat Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Diseases $2,278,080
University of California, Los Angeles Samantha Butler Basic Biology V Assessing the mechanism by which the Bone Morphogenetic Proteins direct stem cell fate $545,962
Cedars-Sinai Medical Center Eduardo Marbán Basic Biology IV Mechanism of heart regeneration by cardiosphere-derived cells $1,367,604
University of California, Los Angeles Dennis Slamon Disease Team Research I THERAPEUTIC OPPORTUNITIES TO TARGET TUMOR INITIATING CELLS IN SOLID TUMORS $19,979,660
University of California, Los Angeles Robert Reiter Early Translational IV Clinical Development of an N-cadherin Antibody to Target Cancer Stem Cells $4,075,668
University of Southern California Mark Humayun Disease Team Therapy Development III Phase 1 Safety Assessment of CPCB-RPE1, hESC-derived RPE Cell Coated Parylene Membrane Implants, in Patients with Advanced Dry Age Related Macular Degeneration $17,128,661
University of California, Los Angeles Dennis Slamon Disease Team Therapy Development III A Phase I dose escalation and expansion clinical trial in patients with advanced solid tumors $6,924,317
Cedars-Sinai Medical Center Dan Gazit Early Translational IV Gene Targeting to Endogenous Stem Cells for Segmental Bone Fracture Healing $5,180,674
University of California, San Diego Karl Willert Tools and Technologies II Homologous recombination in human pluripotent stem cells using adeno-associated virus. $1,659,043
University of California, San Francisco Jason Pomerantz New Faculty Physician Scientist Characterization of Human Skeletal Muscle Stem Cells for Clinical Application $3,084,000
Beckman Research Institute of City of Hope Larry Couture Tools and Technologies III Development of a scalable, practical, and transferable GMP-compliant suspension culture-based differentiation process for cardiomyocyte production from human embryonic stem cells. $899,728
StemCells, Inc. Alexandra Capela Disease Team Therapy Development - Research Restoration of memory in Alzheimer’s disease: a new paradigm using neural stem cell therapy $8,901,641
University of California, San Diego Shyni Varghese Tools and Technologies III Technologies to improve in vivo function of transplanted stem cells $1,393,200
Stanford University Brian Rutt Tools and Technologies II Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters $1,833,348
University of California, Davis J. Leach Tools and Technologies III Multi-modal technology for non-destructive characterization of bioengineered tissues $1,842,792
University of California, Irvine Mathew Blurton-Jones Tools and Technologies III Optimizing the differentiation and expansion of microglial progenitors from human pluripotent stem cells for the study and treatment of neurological disease. $1,147,596
University of California, Los Angeles Sophie Deng Early Translational II Regeneration of Functional Human Corneal Epithelial Progenitor Cells $699,983
Stanford University Sean Wu Basic Biology III Elucidating Molecular Basis of Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells $1,264,248
Stanford University Bertha Chen Early Translational III Autologous iPSC Therapy for Urinary Incontinence $5,025,428
University of California, San Francisco Tippi MacKenzie Transplantation Immunology Maternal and Fetal Immune Responses to In Utero Hematopoietic Stem Cell Transplantation $1,230,869
University of Southern California Toshio Miki Tools and Technologies III Development of a clinical-grade extracorporeal liver support system using human induced pluripotent stem cell-derived hepatic cells $1,257,372
University of California, Berkeley Lin He New Faculty II The roles of non-coding RNAs in the self-renewal and differentiation of pluripotent stem cells $1,406,823
Scripps Research Institute Jeanne Loring Tools and Technologies III User-friendly predictive molecular diagnostic assays for quality control of stem cell derivatives for transplantation and drug discovery $1,784,052
University of California, Davis Laura Marcu Tools and Technologies III Multimodal platform combining optical and ultrasonic technologies for in vivo nondestructive evaluation of engineered vascular tissue constructs $1,834,474
Stanford University Joseph Wu Tools and Technologies III Advanced animal model for predictive preclinical testing of engineered cardiac autografts and allografts $1,713,456
University of California, Davis Alice Tarantal Shared Labs Translational Human Embryonic Stem Cell Shared Research Facility $1,728,111
Sangamo BioSciences, Inc. Fyodor Urnov Strategic Partnership II A Treatment For Beta-thalassemia via High-Efficiency Targeted Genome Editing of Hematopoietic Stem Cells $6,374,150
Stanford University Anthony Oro Tools and Technologies III A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability $1,403,822
University of California, San Francisco Robert Blelloch New Faculty II Mechanisms of small RNA regulation in early embryonic development $2,790,695
University of Southern California Mark Humayun Disease Team Research I Stem cell based treatment strategy for Age-related Macular Degeneration (AMD) $18,904,916
University of California, Los Angeles Kathrin Plath Basic Biology III Discovery of mechanisms that control epigenetic states in human reprogramming and pluripotent cells $1,364,598
University of California, Berkeley Michael Rape Basic Biology III Ubiquitin-dependent control of hESC self-renewal and expansion $1,224,805
ViaCyte, Inc. Allan Robins Disease Team Research I Cell Therapy for Diabetes $22,999,933
University of California, Irvine leif Havton Early Translational II Repair of Conus Medullaris/Cauda Equina Injury using Human ES Cell-Derived Motor Neurons $1,614,231
Stanford University Gary Steinberg Disease Team Research I Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke $18,026,648
University of California, Los Angeles Ali Nsair New Faculty Physician Scientist Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. $95,356
Stanford University Irving Weissman Tools and Technologies II Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs $1,463,881
University of California, Los Angeles Ali Nsair New Faculty Physician Scientist Human Induced Pluripotent Stem Cell-Derived Cardiovascular Progenitor Cells for Cardiac Cell Therapy. $3,004,315
University of California, San Diego Mana Parast New Faculty II Molecular Mechanisms of Trophoblast Stem Cell Specification and Self-Renewal $3,077,918
University of California, San Francisco Mark Anderson Transplantation Immunology Stem cell differentiation to thymic epithelium for inducing tolerance to stem cells $1,314,089
University of Southern California Terrence Town Transplantation Immunology Role of HLA in neural stem cell rejection using humanized mice $353,249
University of California, Riverside Prudence Talbot Shared Labs A Stem Cell Core Facility for Studying Human Embryonic Stem Cell Differentiation $1,679,818
University of California, Davis Walter Boyd Early Translational III Extracellular Matrix Bioscaffold Augmented with Human Stem Cells for Cardiovascular Repair $4,633,149
Humboldt State University Jacob Varkey Bridges CIRM Bridges to Stem Cell Research Certificate Program $3,335,098
University of Southern California Andrew McMahon Research Leadership 10 Repair and regeneration of the nephron $5,672,206
University of California, Davis Frederick Meyers Research Training II Stem Cell Training Program $5,822,412
University of California, San Francisco Ann Zovein New Faculty Physician Scientist Human endothelial reprogramming for hematopoietic stem cell therapy. $2,319,784
Stanford University Michelle Monje Basic Biology IV Stem Cell Mechanisms Governing Discrete Waves of Gliogenesis in the Childhood Brain $1,264,248
Beckman Research Institute of City of Hope David DiGiusto Early Translational II Development of RNA-based approaches to stem cell gene therapy for HIV $3,097,160
Children's Hospital of Orange County Philip Schwartz Early Translational III Immune-Matched Neural Stem Cell Transplantation for Pediatric Neurodegenerative Disease $4,272,774
University of California, Los Angeles Donald Kohn Disease Team Research I Stem Cell Gene Therapy for Sickle Cell Disease $8,833,695
University of California, San Francisco Holger Willenbring Early Translational III Generation of safe and therapeutically effective human induced hepatocyte-like cells $1,544,170
Calimmune, Inc. Geoff Symonds Disease Team Research I GENE-MODIFIED HEMATOPOIETIC STEM/PROGENITOR CELL BASED THERAPY FOR HIV DISEASE $8,278,722
University of California, San Francisco Morton Cowan Early Translational III Gene Correction of Autologous Hematopoietic Stem Cells in Artemis Deficient SCID $3,931,662
University of California, Davis Deborah Lieu Basic Biology IV Induction of Pluripotent Stem Cell-Derived Pacemaking Cells $1,333,800
Sanford-Burnham Medical Research Institute Robert Wechsler-Reya Research Leadership 1 The role of neural stem cells in cerebellar development, regeneration and tumorigenesis $5,226,050
University of California, Los Angeles Donald Kohn Early Translational IV Beta-Globin Gene Correction of Sickle Cell Disease in Hematopoietic Stem Cells $1,652,076
The Salk Institute for Biological Studies Inder Verma Early Translational IV Development of a cell and gene based therapy for hemophilia $2,298,634
Buck Institute for Age Research Xianmin Zeng Shared Labs CIRM Shared Research Laboratory for Stem Cells and Aging $3,478,933
The J. David Gladstone Institutes Deepak Srivastava Early Translational III Direct Cardiac Reprogramming for Heart Regeneration $6,319,110
California State University, Fullerton Nilay Patel Bridges Stem Cell Training Program - A Bridge to Stem Cell Research $3,050,901
The Salk Institute for Biological Studies Juan Carlos Izpisua Belmonte Early Translational III Direct reprogramming towards vascular progenitors for the treatment of ischemia $2,340,000
Buck Institute for Age Research Xianmin Zeng Research Training II CIRM Research Training Program in Stem Cells and Aging $1,472,416
University of California, Los Angeles Gerald Lipshutz Early Translational IV Gene therapy-corrected autologous hepatocyte-like cells from induced pluripotent stem cells for the treatment of pediatric single enzyme disorders $1,801,629
Stanford University Joanna Wysocka Basic Biology III Enhancer-mediated gene regulation during early human embryonic development $1,420,838
California State University, Northridge Cindy Malone Bridges Bridges to Stem Cell Research $3,936,573
Stanford University Alexander Dunn Basic Biology IV Role of mechanical signaling in stem cell self-renewal and differentiation $1,064,224
University of California, Los Angeles Owen Witte Shared Labs CIRM Shared Research Laboratories $1,751,297
Stanford University Judith Shizuru Transplantation Immunology Purified allogeneic hematopoietic stem cells as a platform for tolerance induction $1,233,275
Cedars-Sinai Medical Center Clive Svendsen Disease Team Therapy Development - Research Progenitor Cells Secreting GDNF for the Treatment of ALS $16,961,287
Stanford University Joachim Hallmayer Tissue Collection for Disease Modeling Induced pluripotent stem cells from children with autism spectrum disorders $530,265
Cedars-Sinai Medical Center Clive Svendsen Tools and Technologies II Use of iPS cells (iPSCs) to develop novels tools for the treatment of spinal muscular atrophy. $1,933,022

Pages

© 2013 California Institute for Regenerative Medicine